Ivim Health is a leading telehealth platform specializing in medically managed weight loss. Their "GLP-1 ID" program provides individualized dosing of compounded or brand-name Semaglutide and Tirzepatide. Converts on Paid Order

Targeting: Primary audience includes adults (25–55) with a BMI of 30+ (or 27+ with comorbidities) seeking "physician-backed" alternatives to high-cost retail prescriptions.

Restrictions: No Brand Bidding on "Ivim Health" or related trademarks. No incentivized or "get-paid-to-join" traffic. Marketing must clearly state that compounded medications are not FDA-approved and that results vary by individual. Prohibited tactics include using "before and after" photos without proper disclaimers or promising a "guaranteed" supply during national medication shortages. All email traffic must be 100% CAN-SPAM and TCPA compliant.